Synchron Systems Opiate 2000 ng Reagent (OP2 1 x 250); catalogue no. 475006 for use in conjunction with UniCel DxC 600/800 System(s) and SYNCHRON Systems Drugs of Abuse Testing (DAT) Urine Calibrators. The assay provides a rapid screening procedure for presence of the analyte in urine.
- Company
- Beckman Coulter Inc.
- Recall Initiated
- September 4, 2019
- Posted
- April 20, 2020
- Terminated
- April 28, 2021
- Recall Number
- Z-1751-2020
- Quantity
- 1610 units
- Firm Location
- Brea, CA
Reason for Recall
Cross-reactivity testing may not meet the claims indicated in the Opiate 2000 ng (OP2) Instructions For Use. The presence of certain compounds in urine may result in false positive or false negative patient test results.
Distribution
Distributed throughout the United States and to Puerto Rico. States include: CA, NC, OR, MI, GE, AL, SC, TX, NJ, IA, MS, IN, MA, NC, OH, AZ, LA, MA, NY, PA, KY, WV, MI, WA, CO, IL, VA, FL, KS, MD, ID, DE, NV, OK, AR, HI, WI, NY.
Lot / Code Info
Catalog Number 475006 ; UDI: 15099590222031; Lot Numbers: M904147 and older including M810039, M901087 and M904147) and 4 lots OP2 (M805122, M810039, and M901087. .
Root Cause
Material/Component Contamination
Action Taken
An Urgent Medical Device Recall Letter was sent to customers via either U.S. postal service or email beginning on 9-4-2019. The letter informs customers that studies indicate that cross-reactivity testing may not meet the claims indicated in the Opiate 300 ng (OP) and Opiate 2000 ng (OP2) Instructions For Use (IFU). This letter included the Instructions for Use (IFU) claims versus study results for each product. Customers were informed of which compounds (at specific concentrations or ranges) may result in false positive or false negative test results. The letter indicated that Laboratories should be aware of these findings but that retrospective review of results is not required. Customers were informed that resolution of this issue was handled by revising the Opiate 300 ng (OP) Reagent IFU and the Opiate 2000 ng (OP2) Reagent IFU to update the Cross Reactivity sections. Customers were also requested to provide a copy of the letter to any other laboratory to which they may have forwarded affected product. Customers were requested to acknowledge receipt of the recall notification letter by responding to Beckman Coulter within 10 days either electronically, if the letter was received via email, or manually by completing and return the enclosed Response Form. Customers were instructed to contact the Beckman Coulter Customer Support Center through their website at http://www.beckmancoulter.com/customersupport/support; or by phone at 1-800-854-3633 in the United States and Canada with any questions. Customers outside of the U.S. and Canada were instructed to contact their local Beckman Coulter Representative.